At a glance

ClinicalIndex Comparison Record

Phase 1Enrolling by Invitation· 30 target

Drug / intervention

Antigen-specific IgT cellsbiological

Likely dose

Antigen-specific IgT cells 250 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03170141

NCT03170141Phase 1Enrolling by InvitationOn TrackUpdated 2mo ago

Compare CT.gov

Immunogene-modified Antigen-specific T (IgT) Cells for the Treatment of Glioblastoma Multiforme

Shenzhen Geno-Immune Medical Institute·interventional·Posted May 30, 2017·Updated Apr 24, 2026

In Brief

A Phase 1 clinical trial evaluating Antigen-specific IgT cells for Glioblastoma Multiforme of Brain and Brain Cancer. Currently enrolling by invitation, targeting 30 participants across 1 site.

Detailed Summary

This study aims to treat patients who have been diagnosed with brain cancer glioblastoma multiforme (GBM) including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). The treatment combines two different approaches to fight cancer: immune modulators and antigen-specific T cells. Immune checkpoint antibodies have been tested on various tumors with good outcomes. GBM is known to express increased levels of certain antigens that can be targeted by T cells including chimeric antigen receptor-modified T (CAR-T) cells and tumor antigen specific cytotoxic lymphocytes (CTLs). In this study, the gene-modified T cells specific for GBM antigens will be combined with immune modulatory gene-modified dendritic cells (DCs) as individualized treatment regimens to treat patients.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsGlioblastoma Multiforme of Brain, Brain Cancer

CountriesChina

Collaborators--

Timeline

Phase 1Enrolling by Invitation

20182019202020212022202320242025202620272028

First PostedMay 2017

Enrollment StartMay 2017

TodayJul 2026

Primary CompletionJul 2027

Study CompletionDec 2027

First PostedMay 30, 2017

Enrollment StartMay 31, 2017

Primary CompletionJul 31, 2027

Study CompletionDec 31, 2027

TodayJul 1, 2026

Enrollment to primary: 10.2 yearsPosted 9.1 years agoPrimary completion in 1.1 years

Interventions

Antigen-specific IgT cellsbiological

Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3